Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Marine, Diviné"'
Autor:
Rémy Boussageon, Bernard Avouac, Jean-Louis Montastruc, Patrick Dufour, Nicolas Girerd, Valérie Laigle, David Braunstein, Jean-François Bergmann, Eric Vicaut, Albert Trinh-Duc, Catherine Brun-Strang, François Gueyffier, Béatrice Cazeneuve, Marine Diviné, François Liard, Claire Le Jeunne, Thomas Borel, Pascal Piedbois, Amélie Marsot
Publikováno v:
Therapies. 72:39-49
Resume L’estimation du benefice net permet d’expliciter les fondements des decisions therapeutiques, individuelles et collectives. Cette explicitation est une exigence dans la decision medicale partagee et la pratique de la medecine factuelle ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50c59843e964af16b5d76759731ece05
https://doi.org/10.1016/j.therap.2016.11.057
https://doi.org/10.1016/j.therap.2016.11.057
Autor:
Silvy Laporte, Marine Diviné, Danièle Girault, Pierre Boutouyrie, Olivier Chassany, Michel Cucherat, Hervé de Trogoff, Sophie Dubois, Cecile Fouret, Natalie Hoog-Labouret, Pascale Jolliet, Patrick Mismetti, Raphaël Porcher, Cécile Rey-Coquais, Eric Vicaut
Publikováno v:
Therapies. 71:27-34
Resume Dans un essai clinique randomise, lorsque le resultat sur le critere de jugement principal montre un benefice significatif, les criteres secondaires sont scrutes a la recherche d’effets additionnels du traitement. Cette demarche entraine cep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4396b537a3eba1b4a041b31773ca0cf9
https://doi.org/10.1016/j.therap.2015.11.001
https://doi.org/10.1016/j.therap.2015.11.001
Autor:
Silvy Laporte, Marine Diviné, Danièle Girault, Pierre Boutouyrie, Olivier Chassany, Michel Cucherat, Hervé de Trogoff, Sophie Dubois, Cecile Fouret, Natalie Hoog-Labouret, Pascale Jolliet, Patrick Mismetti, Raphaël Porcher, Cécile Rey-Coquais, Eric Vicaut
Publikováno v:
Therapies. 71:35-41
In a randomised clinical trial, when the result of the primary endpoint shows a significant benefit, the secondary endpoints are scrutinised to identify additional effects of the treatment. However, this approach entails a risk of concluding that the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06140e1c4767392c0e7ed118735c4710
https://doi.org/10.1016/j.therap.2016.01.002
https://doi.org/10.1016/j.therap.2016.01.002
Autor:
Pierre Marquet, Etienne Chatelut, Philippe Froguel, Pierre-Henry Longeray, Céline Verstuyft, Martine Pigeon, François Gueyffier, Samia Mourah, Olivier Perche, Isabelle Diaz, Véronique Ameye, Florent Perin-Dureau, Michèle Morin-Surroca, Anne Tisseau, Natalie Hoog-Labouret, Sylvia Goni, Béatrice Cazeneuve, Marine Diviné, Pascale Augé, Fabrice Barlesi
Publikováno v:
Therapies. 70:11-19
Personalized medicine is based on: 1) improved clinical or non-clinical methods (including biomarkers) for a more discriminating and precise diagnosis of diseases; 2) targeted therapies of the choice or the best drug for each patient among those avai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eda951aa1025e95994526cd86a0d8e42
https://doi.org/10.2515/therapie/2014231
https://doi.org/10.2515/therapie/2014231
Autor:
Etienne Chatelut, Olivier Perche, Pierre-Henry Longeray, Béatrice Cazeneuve, Véronique Ameye, Isabelle Diaz, Anne Tisseau, François Gueyffier, Pascale Augé, Michèle Morin-Surroca, Natalie Hoog-Labouret, Céline Verstuyft, Martine Pigeon, Florent Perin-Dureau, Fabrice Barlesi, Marine Diviné, Samia Mourah, Philippe Froguel, Pierre Marquet, Sylvia Goni
Publikováno v:
Therapies. 70:1-10
Resume La medecine personnalisee repose sur : 1) des methodes cliniques et paracliniques (y compris des biomarqueurs) pour un diagnostic plus discriminant et plus precis des maladies ; 2) des therapies ciblees ou le choix du meilleur traitement parmi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d8b557921b58aa9ccbfebd232c9eef5
https://doi.org/10.2515/therapie/2014230
https://doi.org/10.2515/therapie/2014230
Autor:
Claire Le Jeunne, Thomas Borel, François Gueyffier, Eric Vicaut, David Braunstein, Patrick Dufour, Albert Trinh-Duc, François Liard, Amélie Marsot, Valérie Laigle, Béatrice Cazeneuve, Pascal Piedbois, Marine Diviné, Rémy Boussageon, Jean-François Bergmann, Catherine Brun-Strang, Bernard Avouac, Jean-Louis Montastruc, Nicolas Girerd
Publikováno v:
Therapie. 72(1)
Estimating net benefit makes possible to clarify the basis for therapeutic decisions on an individual and collective level. This clarification is a must in shared medical decision-making and evidence-based medicine. Numerous methods are available, al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6819b615c428b1d11dcfa529588aeeaf
https://pubmed.ncbi.nlm.nih.gov/28159197
https://pubmed.ncbi.nlm.nih.gov/28159197
Autor:
Yongqing Zhang, Satz Mengensatzproduktion, Kazuo Hatanaka, Ji Liu, Poonam Kumari, Hwang Gyun Jeon, Rémy Perdrisot, Hyung-Min Chung, Tiejun Qin, Nobuyoshi Hanaoka, Basab Bagchi, Gi Jin Kim, Per Arne Drabløs, Sandeep Saha, Qi Chen, Marine Diviné, Kodai Kuriyama, Hu Chen, Marta Fichna, Hartmut Merz, Takashi Sonoki, Hiroki Hosoi, Katarzyna Derwich, Veronica Bernard, Druck Reinhardt Druck Basel, Gin-Hyung Hur, Lihui Liu, Shinobu Tamura, Shyamali Dutta, Jyuri Watanuki, Mingjuan Liu, Shogo Murata, Jolanta Rembowska, Bing Li, Hideki Nakakuma, Hye-Sun Kim, Jacob A. Stakkestad, Liping Ye, Sei-Kyung Chang, Li Yu, Doyeun Oh, Danuta Januszkiewicz-Lewandowska, Yue Zhang, Giselle V. Ripoll, Vincent Delwail, Niklas Gebauer, Wolfgang Gebauer, Masaya Shimanuki, Daniel F. Alonso, Mathieu Puyade, Robert Peter Gale, M. Azam Mansoor, Zhijian Xiao, Hye-Gyn Lee, Cécile Tomowiak, Tuphan K. Dolai, Prakas Kumar Mandal, Toshiki Mushino, Hyun-Soo Shin, François Guilhot, Bing Shi, So Young Chong, Moon Ju Jang, Magda Żurawek, Zefeng Xu, Alfred C. Feller, Soumita Choudhuri, Karina Nowicka, Jerzy Nowak, Xiao-Li Du, Natraj Ks, Mokrane Yacoub
Publikováno v:
Acta Haematologica. 129:I-IV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cabc76714ffc3d365cb32125be8b0df9
https://doi.org/10.1159/000351401
https://doi.org/10.1159/000351401
Autor:
Gilles Paintaud, Marine Diviné, Philippe Lechat, Martine Bagot, Isabelle Boucot, Anne d’Andon, Françoise Grudé, Thierry Lecomte, Soyi Liu-Leage, Daniel Olive, Pascal Piedbois, Martine Pigeon, Jean-Louis Pinquier, Jean-François Prost, Gilles Thibault, Christian Vitzling
Publikováno v:
Therapies. 67:319-327
Resume Les anticorps monoclonaux (AcMo) sont tres differents des autres medicaments. Notre objectif a ete d’evaluer si leurs specificites ont des consequences sur leur developpement clinique, leur evaluation par les autorites de sante et leur suivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bba9eeef6bed26b17dc137b6dc75e9c
https://doi.org/10.2515/therapie/2012043
https://doi.org/10.2515/therapie/2012043
Autor:
Gilles Paintaud, Marine Diviné, Philippe Lechat, Martine Bagot, Isabelle Boucot, Anne d’Andon, Françoise Grudé, Thierry Lecomte, Soyi Liu-Leage, Daniel Olive, Pascal Piedbois, Martine Pigeon, Jean-Louis Pinquier, Jean-François Prost, Gilles Thibault, Christian Vitzling
Publikováno v:
Therapies. 67:329-337
Monoclonal antibodies (MoAb) are very different from other drugs. The Round Table aimed to determine whether the specific characteristics of MoAb have repercussions on their clinical development, evaluation by the health authorities, and long-term mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d22ab9a632960e2736719c1274cbdfa
https://doi.org/10.2515/therapie/2012046
https://doi.org/10.2515/therapie/2012046
Autor:
Emmanuel Gyan, J.H. Meerwaldt, Chantal Rieux, Jean Gabarre, Eric Van Den Neste, Pieternella J. Lugtenburg, Pierre Lederlin, Jan Walewski, Christophe Fermé, Pauline Brice, Houchingue Eghbali, Philip Poortmans, Jacques Bosq, Michel Henry-Amar, Geert Jan Creemers, José Thomas, Christian Carrie, Patrice Carde, Oumedaly Reman, Marine Diviné, Johanna Kluin-Nelemans, Michel Blanc, Jérôme Jaubert, Gilles Salles, Anton Hagenbeek, Theodore Girinsky, Mars B. van't Veer, Françoise Berger, Joke W. Baars, Umberto Tirelli, B. Vie, John M. M. Raemaekers, Mathieu Monconduit, Fernando Viseu, Evert M. Noordijk
Publikováno v:
The New England Journal of Medicine, 357, 1916-27
The New England Journal of Medicine, 357, 19, pp. 1916-27
New England Journal of Medicine, 357(19), 1916-1927. Massachussetts Medical Society
New England journal of medicine, 357(19), 1916-1927. Massachussetts Medical Society
New England Journal of Medicine, 357(19), 1916-1927. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 357, 19, pp. 1916-27
New England Journal of Medicine, 357(19), 1916-1927. Massachussetts Medical Society
New England journal of medicine, 357(19), 1916-1927. Massachussetts Medical Society
New England Journal of Medicine, 357(19), 1916-1927. MASSACHUSETTS MEDICAL SOC
Item does not contain fulltext BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cf0f86aed2b9569e0fd3ead1f269ddd
https://doi.org/10.1056/nejmoa064601
https://doi.org/10.1056/nejmoa064601